SomaLogic, Inc. (SLGC)

2.5500 +0.1300 (+5.37%) At close: 04:00PM EDT

SomaLogic, Inc.

2945 Wilderness Place
Boulder, CO 80301
United States
303 625 9000
https://www.somalogic.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 320

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Troy M. Cox M.B.A.	Exec. Chairman	14k	N/A	1964
Dr. Roy Smythe M.D.	CEO & Director	1.27M	N/A	1962
Mr. Shaun M. Blakeman	Chief Financial Officer	316.49k	N/A	1978
Dr. Jason Cleveland Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Dr. Nebojsa Janjic Ph.D.	Chief Science Officer	N/A	N/A	1961
Mr. Ruben Gutierrez J.D.	Gen. Counsel	N/A	N/A	1975
Ms. Alison Marie Roelke	Sr. VP of People & Culture	N/A	N/A	1974
Dr. Stephen A. Williams BS, MB, Ph.D.	Chief Medical Officer	N/A	N/A	1960
Mr. Todd Johnson	Exec. VP of Diagnostics Bus. Unit	N/A	N/A	N/A
Mr. Adam Taich	Exec. VP of Life Sciences Bus. Unit	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Corporate governance

SomaLogic, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.